Paclitaxel Treatment Options in Cleveland, OH

A collection of 304 research studies where Paclitaxel is the interventional treatment. These studies are located in the Cleveland, OH. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Research Study

Recruiting

Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Sinusitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer

NCT05624996

Recruiting

This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or osimertinib) versus the usual treatment alone in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (locally advanced) and cannot be treated by surgery (inoperable). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. IGRT is a type of radiation that uses a computer to create a picture of the tumor, to help guide the radiation beam during therapy, making it more accurate and causing less damage to healthy tissue. Usual chemotherapy used in this trial consists of combinations of the following drugs: cisplatin, carboplatin, paclitaxel, nab-paclitaxel, pemetrexed, and etoposide. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds. Cisplatin works by killing, stopping, or slowing the growth of tumor cells. Carboplatin works in a way similar to the anticancer drug cisplatin but may be better tolerated than cisplatin. Carboplatin works by killing, stopping, or slowing the growth of tumor cells as well. Paclitaxel is in a class of medications called antimicrotubule agents. It works by stopping the growth and spread of tumor cells. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by blocking the action of a certain substance in the body that may help tumor cells multiply. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and deoxyribonucleic acid (DNA) repair and may kill tumor cells. Immunotherapy with durvalumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Osimertinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Adding SBRT to the usual treatment of IGRT with chemotherapy and immunotherapy may be more effective at treating patients with locally-advanced non-small cell lung cancer than giving the usual treatment alone. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/14/2025

Locations: Cleveland Clinic Akron General, Akron, Ohio +25 locations

Cleveland Clinic Akron General, Akron, Ohio

UH Seidman Cancer Center at UH Avon Health Center, Avon, Ohio

UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio

Cleveland Clinic Mercy Hospital, Canton, Ohio

Aultman Health Foundation, Canton, Ohio

Miami Valley Hospital South, Centerville, Ohio

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio

Case Western Reserve University, Cleveland, Ohio

Riverside Methodist Hospital, Columbus, Ohio

Grant Medical Center, Columbus, Ohio

Doctors Hospital, Columbus, Ohio

Miami Valley Hospital, Dayton, Ohio

Premier Blood and Cancer Center, Dayton, Ohio

Dayton Physician LLC - Englewood, Dayton, Ohio

Miami Valley Hospital North, Dayton, Ohio

Delaware Health Center-Grady Cancer Center, Delaware, Ohio

Grady Memorial Hospital, Delaware, Ohio

Dublin Methodist Hospital, Dublin, Ohio

Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio

Miami Valley Cancer Care and Infusion, Greenville, Ohio

OhioHealth Mansfield Hospital, Mansfield, Ohio

OhioHealth Marion General Hospital, Marion, Ohio

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio

Mercy Health - Perrysburg Hospital, Perrysburg, Ohio

Upper Valley Medical Center, Troy, Ohio

University of Cincinnati Cancer Center-West Chester, West Chester, Ohio

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8

Learn More ›

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

NCT04165070

Recruiting

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC. This study is one of the pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

07/10/2025

Locations: Cleveland Clinic Main ( Site 0006), Cleveland, Ohio +1 locations

Conditions: Carcinoma, Non-Small-Cell Lung

Learn More ›

Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)

NCT05116189

Active Not Recruiting

The primary objective is to compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by the investigator. The hypotheses are that pembrolizumab plus paclitaxel with or without bevacizumab is superior to placebo plus paclitaxel with or without bevacizumab, with respect to PFS per RECIST 1.1 as assessed by the inv... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

07/10/2025

Locations: Aultman Hospital-Oncology Clinical Trials ( Site 0009), Canton, Ohio +1 locations

Conditions: Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms

Learn More ›

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

NCT04306900

Completed

This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.

Gender:

ALL

Ages:

Between 18 years and 110 years

Trial Updated:

07/09/2025

Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio +1 locations

Conditions: Solid Tumor, Adult

Learn More ›

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

NCT04498117

Active Not Recruiting

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

07/07/2025

Locations: SCC at UH Geauga Medical Center, Chardon, Ohio +8 locations

Conditions: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms

Learn More ›

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

NCT04001829

Active Not Recruiting

This phase II trial studies whether a prior germline predictor of taxane-induced peripheral neuropathy (TIPN) can help identify a subgroup of patients who are at higher risk of chemotherapy-induced peripheral neuropathy in African American patients with stages I-III breast cancer. The study also investigates whether docetaxel maybe work better than paclitaxel with regard to TIPN rate/severity and dose reductions.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/26/2025

Locations: Cleveland Clinic Akron General, Akron, Ohio +39 locations

Cleveland Clinic Akron General, Akron, Ohio

UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio

Strecker Cancer Center-Belpre, Belpre, Ohio

Geauga Hospital, Chardon, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

Case Western Reserve University, Cleveland, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Mount Carmel East Hospital, Columbus, Ohio

Columbus Oncology and Hematology Associates Inc, Columbus, Ohio

Riverside Methodist Hospital, Columbus, Ohio

Grant Medical Center, Columbus, Ohio

The Mark H Zangmeister Center, Columbus, Ohio

Mount Carmel Health Center West, Columbus, Ohio

Doctors Hospital, Columbus, Ohio

Delaware Health Center-Grady Cancer Center, Delaware, Ohio

Grady Memorial Hospital, Delaware, Ohio

Dublin Methodist Hospital, Dublin, Ohio

Central Ohio Breast and Endocrine Surgery, Gahanna, Ohio

Mount Carmel Grove City Hospital, Grove City, Ohio

Fairfield Medical Center, Lancaster, Ohio

Saint Rita's Medical Center, Lima, Ohio

OhioHealth Mansfield Hospital, Mansfield, Ohio

Marietta Memorial Hospital, Marietta, Ohio

OhioHealth Marion General Hospital, Marion, Ohio

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio

UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio

Knox Community Hospital, Mount Vernon, Ohio

Licking Memorial Hospital, Newark, Ohio

Newark Radiation Oncology, Newark, Ohio

University Hospitals Parma Medical Center, Parma, Ohio

Mercy Health Perrysburg Cancer Center, Perrysburg, Ohio

Southern Ohio Medical Center, Portsmouth, Ohio

University Hospitals Portage Medical Center, Ravenna, Ohio

UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio

Saint Vincent Mercy Medical Center, Toledo, Ohio

Mercy Health - Saint Anne Hospital, Toledo, Ohio

University Hospitals Sharon Health Center, Wadsworth, Ohio

Saint Ann's Hospital, Westerville, Ohio

UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio

Genesis Healthcare System Cancer Care Center, Zanesville, Ohio

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8

Learn More ›

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

NCT01275677

Completed

This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving chemotherapy after surgery may kill more tumor cells. Monoclonal antibodies,... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/25/2025

Locations: Summa Health System - Akron Campus, Akron, Ohio +97 locations

Summa Health System - Akron Campus, Akron, Ohio

Summa Health System - Barberton Campus, Barberton, Ohio

Cleveland Clinic Cancer Center Beachwood, Beachwood, Ohio

UHHS-Chagrin Highlands Medical Center, Beachwood, Ohio

Mary Rutan Hospital, Bellefontaine, Ohio

Strecker Cancer Center-Belpre, Belpre, Ohio

Toledo Clinic Cancer Centers-Bowling Green, Bowling Green, Ohio

Aultman Health Foundation, Canton, Ohio

Miami Valley Hospital South, Centerville, Ohio

Geauga Hospital, Chardon, Ohio

Adena Regional Medical Center, Chillicothe, Ohio

Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio

Oncology Hematology Care Inc-Mercy West, Cincinnati, Ohio

The Christ Hospital, Cincinnati, Ohio

University of Cincinnati Cancer Center-UC Medical Center, Cincinnati, Ohio

Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio

Oncology Hematology Care Inc-Anderson, Cincinnati, Ohio

Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio

Bethesda North Hospital, Cincinnati, Ohio

Oncology Hematology Care Inc-Blue Ash, Cincinnati, Ohio

TriHealth Cancer Institute-Westside, Cincinnati, Ohio

TriHealth Cancer Institute-Anderson, Cincinnati, Ohio

Case Western Reserve University, Cleveland, Ohio

MetroHealth Medical Center, Cleveland, Ohio

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland, Ohio

Cleveland Clinic Foundation, Cleveland, Ohio

North Coast Cancer Care-Clyde, Clyde, Ohio

Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Mount Carmel East Hospital, Columbus, Ohio

Columbus Oncology and Hematology Associates Inc, Columbus, Ohio

Riverside Methodist Hospital, Columbus, Ohio

Columbus NCI Community Oncology Research Program, Columbus, Ohio

Grant Medical Center, Columbus, Ohio

The Mark H Zangmeister Center, Columbus, Ohio

Mount Carmel Health Center West, Columbus, Ohio

Doctors Hospital, Columbus, Ohio

Grandview Hospital, Dayton, Ohio

Good Samaritan Hospital - Dayton, Dayton, Ohio

Miami Valley Hospital, Dayton, Ohio

Miami Valley Hospital North, Dayton, Ohio

Dayton NCI Community Oncology Research Program, Dayton, Ohio

Delaware Health Center-Grady Cancer Center, Delaware, Ohio

Delaware Radiation Oncology, Delaware, Ohio

Grady Memorial Hospital, Delaware, Ohio

Hematology Oncology Center Incorporated, Elyria, Ohio

Mercy Cancer Center-Elyria, Elyria, Ohio

Oncology Hematology Care Inc-Healthplex, Fairfield, Ohio

Blanchard Valley Hospital, Findlay, Ohio

Atrium Medical Center-Middletown Regional Hospital, Franklin, Ohio

Wayne Hospital, Greenville, Ohio

Cleveland Clinic Cancer Center Independence, Independence, Ohio

Kettering Medical Center, Kettering, Ohio

Fairfield Medical Center, Lancaster, Ohio

Lancaster Radiation Oncology, Lancaster, Ohio

Saint Rita's Medical Center, Lima, Ohio

Lima Memorial Hospital, Lima, Ohio

OhioHealth Mansfield Hospital, Mansfield, Ohio

Cleveland Clinic Cancer Center Mansfield, Mansfield, Ohio

Marietta Memorial Hospital, Marietta, Ohio

Saint Luke's Hospital, Maumee, Ohio

Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio

Toledo Radiation Oncology at Northwest Ohio Onocolgy Center, Maumee, Ohio

Hillcrest Hospital Cancer Center, Mayfield Heights, Ohio

UH Seidman Cancer Center at Landerbrook Health Center, Mayfield Heights, Ohio

UH Seidman Cancer Center at Lake Health Mentor Campus, Mentor, Ohio

UH Seidman Cancer Center at Southwest General Hospital, Middleburg Heights, Ohio

Knox Community Hospital, Mount Vernon, Ohio

Licking Memorial Hospital, Newark, Ohio

Newark Radiation Oncology, Newark, Ohio

Fisher-Titus Medical Center, Norwalk, Ohio

Saint Charles Hospital, Oregon, Ohio

Toledo Clinic Cancer Centers-Oregon, Oregon, Ohio

Southern Ohio Medical Center, Portsmouth, Ohio

North Coast Cancer Care, Sandusky, Ohio

UH Seidman Cancer Center at Firelands Regional Medical Center, Sandusky, Ohio

Springfield Regional Medical Center, Springfield, Ohio

Trinity's Tony Teramana Cancer Center, Steubenville, Ohio

Cleveland Clinic Cancer Center Strongsville, Strongsville, Ohio

ProMedica Flower Hospital, Sylvania, Ohio

Mercy Hospital of Tiffin, Tiffin, Ohio

ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio

Mercy Health - Saint Vincent Hospital, Toledo, Ohio

University of Toledo, Toledo, Ohio

Toledo Community Hospital Oncology Program CCOP, Toledo, Ohio

Mercy Health - Saint Anne Hospital, Toledo, Ohio

Toledo Clinic Cancer Centers-Toledo, Toledo, Ohio

Upper Valley Medical Center, Troy, Ohio

University Hospitals Sharon Health Center, Wadsworth, Ohio

South Pointe Hospital, Warrensville Heights, Ohio

Fulton County Health Center, Wauseon, Ohio

University of Cincinnati Cancer Center-West Chester, West Chester, Ohio

Saint Ann's Hospital, Westerville, Ohio

UH Seidman Cancer Center at Saint John Medical Center, Westlake, Ohio

Clinton Memorial Hospital/Foster J Boyd Regional Cancer Center, Wilmington, Ohio

Cleveland Clinic Wooster Family Health and Surgery Center, Wooster, Ohio

Wright-Patterson Medical Center, Wright-Patterson Air Force Base, Ohio

Greene Memorial Hospital, Xenia, Ohio

Genesis Healthcare System Cancer Care Center, Zanesville, Ohio

Conditions: HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7

Learn More ›

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

NCT06486441

Recruiting

The goal of this clinical study is to find out how the study drug, sacituzumab govitecan (SG) works in participants with endometrial cancer who have received prior treatment with platinum-based chemotherapy and immunotherapy, versus the treatment of physician's choice (TPC). The primary objectives of this study are to evaluate the effect of SG compared to TPC on progression-free survival (PFS) as assessed by blinded independent central review (BICR) and overall survival (OS).

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/23/2025

Locations: Cleveland Clinic, Cleveland, Ohio +1 locations

Conditions: Endometrial Cancer

Learn More ›

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

NCT03884556

Completed

This is a phase 1/1b study of TTX-030, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, and anti-tumor activity of TTX-030 as a single agent and in combination with an approved anti-PD-1 immunotherapy and standard chemotherapies... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/13/2025

Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio

Conditions: Solid Tumor, Lymphoma

Learn More ›

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

NCT04008797

Recruiting

The primary objective of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s), and to determine the optimal dose of E7386 in combination with lenvatinib in endometrial carcinoma (EC) (for EC Dose Optimization Part only).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

06/11/2025

Locations: MetroHealth Medical Center, Cleveland, Ohio +1 locations

Conditions: Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Learn More ›

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

NCT02453282

Active Not Recruiting

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) wild-type locally advanced or metastatic NSCLC

Gender:

ALL

Ages:

Between 18 years and 130 years

Trial Updated:

06/06/2025

Locations: Research Site, Cleveland, Ohio

Conditions: Non-Small-Cell Lung Carcinoma NSCLC

Learn More ›

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

NCT06619236

Recruiting

This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemothe... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

06/02/2025

Locations: MetroHealth Medical Center, Cleveland, Ohio +1 locations

Conditions: Platinum-resistant Ovarian Cancer

Learn More ›

Browse Paclitaxel Treatment Options in Other Ohio Cities

Paclitaxel treatment options in Columbus

Paclitaxel treatment options in Cincinnati